Haloette Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber, you may be fielding questions from patients who can't find Haloette at their pharmacy. This clinical brief covers the current 2026 status of Haloette availability, evidence-based prescribing strategies for managing access issues, and practical tools you can recommend to affected patients.

Current Status: Is Haloette in a National Shortage?

As of 2026, Haloette (etonogestrel 0.12 mg/day / ethinyl estradiol 0.015 mg/day vaginal ring) is not listed on the FDA Drug Shortages Database or the ASHP shortage list. There is no declared manufacturer-level shortage. Mayne Pharma's Haloette is produced by Mithra at their CDMO facility in Belgium, and supply at the national level appears stable.

However, patients are experiencing localized stock-outs at the pharmacy level. This reflects distribution patterns, formulary-driven demand shifts, and the variable stocking decisions of individual pharmacy locations — not a supply chain emergency. Clinically, the most important point is that two other FDA-approved bioequivalent generics (EluRyng and EnilloRing) and brand NuvaRing remain available and are appropriate substitutes.

Pharmacological Context: Generic Bioequivalence

All FDA-approved etonogestrel/ethinyl estradiol vaginal rings — NuvaRing (brand), EluRyng (Amneal), EnilloRing, and Haloette (Mayne Pharma/Mithra) — contain the same active ingredients at the same doses and have demonstrated bioequivalence to NuvaRing in pharmacokinetic studies. Each ring contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol and releases 0.12 mg/day etonogestrel and 0.015 mg/day ethinyl estradiol via transmucosal vaginal absorption.

From a clinical standpoint, there is no therapeutic reason to prefer one FDA-approved ring over another. Patient preference for a specific product (based on packaging, prior experience, or perceived tolerability differences) may exist, but these are not pharmacologically meaningful for most patients. Providers can confidently authorize generic substitution between ring products.

Prescribing Strategies for Patients Who Can't Find Haloette

Consider the following approaches when a patient reports difficulty filling their Haloette prescription:

Write for the drug class, not the brand: Prescribe "etonogestrel/ethinyl estradiol vaginal ring" (generic name) with "Brand/Generic substitution permitted" or specify "Haloette, EluRyng, or EnilloRing." This gives pharmacies maximum flexibility.

Provide a 90-day supply when appropriate: A 90-day supply prescription allows patients to use mail-order pharmacy, reduces the frequency of access issues, and may lower out-of-pocket costs for insured patients.

Bridge with a combined oral contraceptive if needed: If a patient cannot access any ring and is at risk of a gap in contraceptive coverage, prescribing a short course of a combined oral contraceptive (COC) is a reasonable bridge. Discuss starting timing to maintain continuous coverage.

Consider long-acting options for patients who repeatedly face access issues: Patients who repeatedly encounter stock-outs may benefit from a discussion about Nexplanon (3-year etonogestrel implant), Annovera (1-year ring), or a hormonal IUD — all of which eliminate monthly pharmacy visits.

ACA Contraceptive Mandate: Insurance Coverage Guidance for Patients

Under the ACA, most non-grandfathered private insurance plans must cover at least one contraceptive in each category — including at least one vaginal ring — at $0 cost sharing. Many plans cover generic rings (including Haloette) at $0 and charge a copay for brand NuvaRing. If a patient's plan only covers a different generic at $0, you may be able to obtain a medical necessity exception if there is a clinical reason for Haloette specifically.

For patients without insurance or with high cost-sharing, GoodRx and SingleCare coupons can reduce the cost of any generic ring to $37–$45 at participating pharmacies. Cash retail prices range from $85 to $199 per ring without discount assistance.

Safety Considerations When Switching Ring Products

Patients switching between ring products (e.g., from Haloette to EluRyng or NuvaRing) during an active cycle can continue their existing schedule. There is no clinical evidence to support a washout period or added backup contraception requirement when switching between bioequivalent etonogestrel/ethinyl estradiol vaginal rings mid-cycle.

Patients switching from the vaginal ring to a COC or patch should follow standard initiation guidance (quick start or first-day start) and use backup contraception for 7 days if not starting within 5 days of a period.

Tools to Recommend to Patients

Directing patients to medfinder can significantly reduce care interruptions from pharmacy stock-outs. medfinder calls pharmacies on the patient's behalf to identify which ones have Haloette (or a specified equivalent) in stock and texts results directly to the patient. This is especially useful for patients in areas with limited pharmacy access or for those who have difficulty navigating the phone system.

Summary for Clinical Practice

No declared national shortage of Haloette as of 2026; localized stock-outs are a pharmacy stocking issue

EluRyng, EnilloRing, and NuvaRing are clinically equivalent substitutes; authorize generic substitution liberally

Write prescriptions for "etonogestrel/ethinyl estradiol vaginal ring" with substitution permitted to maximize pharmacy flexibility

Offer COC bridge therapy for patients facing an imminent coverage gap

Discuss long-acting options (Nexplanon, Annovera, hormonal IUD) for patients who repeatedly encounter access issues

See also: How to Help Your Patients Find Haloette in Stock: A Provider's Guide.